Pharmaceuticals

Recently, Celera Corporation (CRA) submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its KIF6 test, which detects a variant in a gene called KIF6. Data from various researches have shown that approximately 60% of the studied population has this gene...

CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) announced today that it has entered into a definitive agreement with FCB I Holdings Inc. under which FCB, through a wholly-owned subsidiary, will acquire all of the outstanding common stock of CPEX for $27.25 per share in cash. The transaction price...

Recently, Celera Corporation (CRA) submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its KIF6 test, which detects a variant in a gene called KIF6. Data from various researches have shown that approximately 60% of the studied population has this gene...

Eli Lilly's (NYSE: LLY) Effient: 3.1% NRx's of Plavix Market; Citi Assumes 2010 US Sales of $90M. Effient weekly NRx/TRx of 6,156/16,222 vs. Plavix at 189,487/ 623,301. Effient is flat priced at $5.40/day. Cymbalta: $2.5B Annual Run Rate Implied by 4-Wk Avg. TRx's vs. Citi's 2010E US Sales of $2.8B...

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that fidaxomicin, the Company's lead product candidate, has been granted orphan drug designation from the U.S. Food and Drug Administration for the treatment of pediatric Clostridium difficile infection. This orphan drug designation...

Forest Laboratories' (NYSE: FRX) Lexapro posted wkly NRx/TRx of 212,830 (-5%)/539,550(-5%), with SSRI+SNRI market share of 14.3%. Rolling 4week/12week NRx growth rates were -6%/-7% & TRx growth rates were -6%/-7%. Lexapro 5mg/10mg/20mg tabs are priced at a WAC of $2.98/$3.11/$3.25/day. Lexapro...

Yesterday, Inspire announced that denufosol failed to meet its primary and secondary endpoints in the TIGER-2 Phase III study in cystic fibrosis (CF), Piper Jaffray reports. “We are downgrading Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) to a Neutral from an Overweight and lowering our price...

CoreSite Realty Corporation (NYSE: COR) today announced that Jeff Finnin has joined the company as Chief Financial Officer. Mr. Finnin will succeed Deedee Beckman effective January 24, 2011.

Spectrum Pharmaceuticals (NasdaqGS: SPPI) today announced it submitted a supplemental New Drug Application with the U.S. Food and Drug Administration for a Ready-to-Use formulation of FUSILEV for Injection. This submission is in support of FUSILEV's use in colorectal cancer, which is currently...

Piper Jaffray has downgraded Inspire Pharmaceuticals (NASDAQ: ISPH) from Overweight to Neutral and has lowered the price target from $10 to $4.

Kevin Matras shows the right way to find great growth stocks at an excellent value. Highlighted stocks include DX, HITK, OI, TECD and WRLD. DYNEX CAP INC (DX): Free Stock Analysis Report HI TECH PHARMA (HITK): Free Stock Analysis Report OWENS-ILLINOIS (OI): Free Stock Analysis Report TECH DATA CORP...

Hearing unconfirmed rumors that the vice president of Lannett Company (NYSE: LCI) retired today in an 8K filing.

Missouri-based agricultural company, Monsanto Company (MON) is scheduled to report its first quarter results on January 6, 2010. The current Zacks Consensus Estimate for the first quarter is a penny per share. FourthQuarter & Fiscal 2010 Summary On October 6, Monsanto announced weak...

Missouri-based agricultural company, Monsanto Company (MON) is scheduled to report its first quarter results on January 6, 2010. The current Zacks Consensus Estimate for the first quarter is a penny per share. FourthQuarter & Fiscal 2010 Summary On October 6, Monsanto announced weak...